Clinical trial · Interventional
Study of ExAblate Focused Ultrasound Ablation of Breast Cancer
Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
The goal of this prospective, non-randomized, single-arm, multi site, international study is to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the ablation of breast cancer and of MRI. The goal of MRgFUS ablation of breast cancer is to plan and ablate the entire tumor volume in a treatable and device accessible location.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ExAblate MRgFUS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ExAblate
- interventionNames
- Device: ExAblate MRgFUS
Primary outcomes (2)
- measure
- Adverse Events
- timeFrame
- 5 weeks post treatment
- description
- To evaluate the incidence and severity of the ExAblate MRgFUS device-related complications to establish the safety profile of the ExAblate ablation of breast cancer visible on contrast-enhanced MRI with 5-10 mm margins around the primary tumor
- measure
- Histopathological analyses
- timeFrame
- 5 weeks post treatment
- description
- To estimate the effectiveness of ExAblate MRgFUS to ablate 100% of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women age 18 years with invasive breast cancer 2. Patient with contrast-enhanced MR imaging confirming a single focal breast lesion less than 2 cm in diameter 3. Lesion clearly seen on contrast-enhanced MR and in a treatable location 4. Patient who is willing to undergo and be scheduled for sentinel lymph node biopsy 5. Patient scheduled and consented to surgical (lumpectomy or mastectomy) resection of the breast cancer 6. Patient with clinical Stage I disease: T1 M0 N0 7. Patient who signs an informed consent form for screening, SLNB, ablation, and follow-up visits. Exclusion Criteria: 1. Invasive lobular carcinoma; 2. DCIS without invasive components on core biopsy; 3. Tamoxifen, Aromatase Inhibitors, and Neoadjuvant chemotherapy within 30 days prior to ExAblate. 4. Prior XRT or ablative therapy to the target breast; 5. Patients currently receiving anticoagulation therapy within the previous 14 days; 6. Lesions difficult to target (\<1 cm from skin, nipple or the rib cage), as visualized on pre-therapy MRI; 7. Microcalcifications as the only sign of breast cancer on imaging studies; 8. Extensive intraductal components (EIC) on core biopsy. 9. Patients with breast implants; 10. Patients with prior surgical clips or other markers at the site of the breast tumor; 11. Patients with severe cerebrovascular disease (multiple CVA or CVA within 6 months); 12. hemolytic anemia (hematocrit \< 30); 13. Pregnant or lactating, post-partum women; 14. Patient overall health status of ASA \>2 15. Patient with active and ongoing infection at any body site; 16. Poor blood glucose control. 17. Severe hypertension 18. Patients with unstable cardiac status 19. Contraindication to MR or ExAblate ablation therapy 20. Patient with history of deep vein thrombosis 21. With history of pulmonary embolism; 22. Patient with sleep apnea; 23. Patient with airway problems; 24. Patient with severe claustrophobia; 25. Patient with non-MRI compatible implanted metal devices; 26. Patient with difficulty lying prone and still for up to 3 hours (180 minutes) in the MR unit; 27. Patient who cannot fit comfortably in the magnet or patients \>250 lbs; 28. Patient with prior reaction to contrast agent; 29. Patient with history of grand mal seizures; 30. Patient with severely impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73m2 and/or who is on dialysis;
References
Publications (0)
Data not yet available